Oxurion N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBGNF research report →
About the company
Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline includes THR-149, a plasma kallikrein inhibitor currently in Phase II development for diabetic macular edema (DME), and THR-687, an integrin antagonist also undergoing Phase II trials for DME.
- CEO
- Thomas Graney
- IPO
- 2007
- Employees
- 27
- HQ
- Leuven, BE
Price Chart
- Market Cap
- $433.72M
- P/E
- -0.02
- P/S
- 0.38
- P/B
- -0.01
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -590.81%
- Net Margin
- -671.71%
- ROE
- 29.96%
- ROIC
- 341.92%
- Revenue
- $3.00K · -98.86%
- Net Income
- $119.00K · 100.63%
- EPS
- $0.09 · 100.08%
- Op Income
- $382.00K
- FCF YoY
- 78.82%
- 52W High
- $2.00
- 52W Low
- $0.17
- 50D MA
- $0.17
- 200D MA
- $0.18
- Beta
- 0.35
- Avg Volume
- 0
Get TickerSpark's AI analysis on TBGNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TBGNF coverage
Recent articles, reports, and earnings notes.
No research on TBGNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TBGNF report →Similar companies
Peers in the same neighborhood.